

Van: [CCMO - Bevoegde Instantie / Competent Authority](#)
Aan: [ccmo_frontoffice](#)
Onderwerp: FW: Digital Submission Synopsis Clinical Study Report research file NL69548.056.19
Datum: woensdag 27 januari 2021 15:00:26
Bijlagen: [image001.png](#)
[A1 -Cover letter CCMO, dated 25 January 2021.pdf](#)
[M2 – Synopsis of CSR RDN-929-103, dated 21 December 2020.pdf](#)

Voor Marjolein

5.1.2.e

Van: 5.1.2.e <5.1.2.e@qps.com>
Verzonden: maandag 25 januari 2021 14:21
Aan: CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>
CC: 5.1.2.e <5.1.2.e@qps.com>
Onderwerp: Digital Submission Synopsis Clinical Study Report research file NL69548.056.19

Dear CCMO,

Herewith QPS Netherlands B.V. informs you that the synopsis of the clinical study report of the Rodin Therapeutics study “A two-part parallel group study to assess the safety, tolerability and pharmacokinetic (PK) profile of multiple oral doses of RDN-929 in healthy older adults and subjects with early symptomatic Alzheimer’s Disease” registered as NL69548.056.19 has been uploaded in Toetsingonline.

The following documents are enclosed:

- A1 - Cover letter CCMO, dated 25 January 2021
- M2 – Synopsis CSR RDN-929-103, dated 21 December 2020

With Kind regards/Met vriendelijke groeten,



5.1.2.e
5.1.2.e
QPS Netherlands BV | Petrus Campersingel 123 | 9713
AG Groningen | The Netherlands
Tel + 31 50 368 5.1.2.e
Email 5.1.2.e@qps.com | Web www.qps.com

Please note that I am not in the office on Friday

This email or fax and any attachments may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments. Thank you.

QPS is a GLP/GCP-compliant CRO that supports discovery, preclinical, and clinical drug development. We provide quality services in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research to clients worldwide. Our 30+ regional laboratories, clinical facilities and offices are located in North America, Europe, India and Asia. For more information, visit <http://www.qps.com>.